SEC Form 4 · accession 0001562180-19-000862
ARRAY BIOPHARMA INC · ARRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew R Robbins
Officer — COO
Period of report
Feb 6, 2019
Accepted (ET)
Feb 8, 2019 · 6:36 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100412
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 6, 2019 | M | 37,500 | $8.20 | A | 212,120 | D | |
| Common Stock | Feb 6, 2019 | M | 87,500 | $4.63 | A | 299,620 | D | |
| Common StockF1 | Feb 6, 2019 | S | 239,626 | $20.025 | D | 59,994 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $8.20 | Feb 6, 2019 | M | 37,500 | D | — | Mar 2, 2025 | Common Stock | 37,500 | 12,500 | D |
| Stock Option (Right to Buy)F3 | $4.63 | Feb 6, 2019 | M | 87,500 | D | — | Apr 1, 2024 | Common Stock | 87,500 | 0 | D |
Explanation of responses
- F1The price reported for these shares is the weighted average sale price of transactions made at prices from $20.00 to $20.20. Details of actual prices for shares sold are available from the Issuer upon request.
- F2The option vests in four equal annual installments beginning on March 2, 2016.
- F3The option vests in four equal annual installments beginning on April 1, 2015.